Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial.
about
The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agentsIron therapy in anaemic adults without chronic kidney diseaseErythropoietin or darbepoetin for patients with cancerRole of iron supplementation to erythropoiesis stimulating agents in the management of chemotherapy-induced anemia in cancer patientsErythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient dataErythropoiesis-stimulating agents for anaemia in chronic heart failure patientsErythropoietin or Darbepoetin for patients with cancerFerrous sulfate supplementation causes significant gastrointestinal side-effects in adults: a systematic review and meta-analysisSafety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: systematic review and meta-analysis of randomised clinical trialsPrevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v. ironIron deficiency in gastrointestinal oncologySCT in Jehovah's Witnesses: the bloodless transplantErythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes.A European patient record study on diagnosis and treatment of chemotherapy-induced anaemia.When is high-dose intravenous iron repletion needed? Assessing new treatment options.Overview of supportive care in patients receiving chemotherapy: antiemetics, pain management, anemia, and neutropenia.Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemiaA hospital-based cost minimization study of the potential financial impact on the UK health care system of introduction of iron isomaltoside 1000Evaluation of anaemia in patients with multiple myeloma and lymphoma: findings of the European CANCER ANAEMIA SURVEY.Flexible dosing with Darbepoetin alfa for the treatment of chemotherapy-induced anemia.Efficacy and safety of oral lactoferrin supplementation in combination with rHuEPO-beta for the treatment of anemia in advanced cancer patients undergoing chemotherapy: open-label, randomized controlled study.Update of a comparative analysis of cost minimization following the introduction of newly available intravenous iron therapies in hospital practice.Biosimilar epoetin α is as effective as originator epoetin-α plus liposomal iron (Sideral®), vitamin B12 and folates in patients with refractory anemia: A retrospective real-life approach.Intravenous Iron Therapy in Patients with Iron Deficiency Anemia: Dosing Considerations.Evolving treatment strategies for anaemia in cancer: experience with epoetin beta.Comparative cost efficiency across the European G5 countries of originators and a biosimilar erythropoiesis-stimulating agent to manage chemotherapy-induced anemia in patients with cancerCanadian supportive care recommendations for the management of anemia in patients with cancer.The use of darbepoetin alfa for the treatment of chemotherapy-induced anaemia.Is there any role of intravenous iron for the treatment of anemia in cancer?Iron Deficiency Anemia Coexists with Cancer Related Anemia and Adversely Impacts Quality of Life.The development of erythropoietic agents in oncology.Anaemia management strategies: optimising treatment using epoetin beta (NeoRecormon).Epoetin alfa: basic biology and clinical utility in cancer patients.Iron metabolism and iron supplementation in cancer patientsEpoetin beta in oncology: examining the current evidence.Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemiaCurrent and future options for the treatment of chemotherapy-induced anaemia.The role of intravenous iron in the treatment of anemia in cancer patientsIntravenous iron dextran as a component of anemia management in chronic kidney disease: a report of safety and efficacy.Beyond efficacy and safety-the need for convenient and cost-effective iron therapy in health care
P2860
Q24186166-CA87B3F8-9016-4ED3-853D-7D7CB547C0C3Q24187098-2D1E7D6D-9403-4DD0-8362-934478DA5437Q24202335-79E68F59-9C76-4437-B4FA-3FF9F86EF71DQ24203798-FCD6EC20-C6FD-403C-88D6-03752029B5F6Q24240202-2374CBC7-9209-463B-8465-31C4A033489CQ24241045-C11BEBF2-4995-4212-95EB-9AF2D6330338Q24245464-00A433F1-89DE-460F-9C7E-2CE6796EA607Q26822051-F440F887-A142-46C3-828E-EEC113839736Q26829377-0F4215E0-49E8-4AA2-AD1E-69A9395CB630Q27004170-F9966C00-62D6-44D4-812F-AC5A204C019EQ27023196-1B10C661-B29F-4634-BD8F-959C84758EC3Q28267204-741B36C8-A312-4391-82EC-C0B6D67193FBQ33630871-DEDA92C0-D4FC-4B4E-AB40-ABA8654DAFD9Q33848929-90119DBC-F140-4383-B149-70F46A03D277Q34574079-B19AB9BA-A2AB-42F2-888C-D8DF7E4869D7Q34635638-28288B19-C7B3-4A45-AB0E-DB3CD1918982Q34662889-EE974921-AD09-4387-B708-24C1B20AC85AQ34764865-4311D2C0-53F2-4D94-A725-1E230FB11944Q35104268-194808E5-E831-41A5-B1F3-9E39B5FD36AEQ35166812-70AEA72A-533E-45FD-B787-4964CE6FD720Q35584219-7C1DA87D-ADA7-4F01-8625-E7A482896ACCQ35660777-33616B96-7E21-4C83-B858-2AC1121A27C1Q35802841-3AFDB2A5-DFF7-4815-80EA-F3EB718C5BF5Q35898038-8A1D4645-27D0-4351-9F3C-CB3AA600FBC3Q35919230-FCBBFA2D-60CF-4601-A651-B844DF3655A3Q35949310-1996A375-0F0A-4E82-9ADC-7C079D340B69Q36029750-F0203DC4-F106-4AFE-803C-B6FC0284A75CQ36082066-21D4503E-5732-41D6-B59E-EEF298900DDAQ36108113-F4AD2B56-5A26-415F-AB89-591847AE3D28Q36147237-03D98472-E348-4DD4-A024-2842CED503BCQ36219651-984B82C2-798A-4145-B1BF-184D2DD18357Q36294786-828B8186-9CD5-45F8-8B97-C94BCDBA0AFAQ36334861-0D65229F-CE71-4BA9-8E24-256FEF0361DDQ36371665-02E24E53-45A5-43F7-B1C4-5D9B35323D49Q36429666-E259E92C-A8B6-4F41-A43A-491B6254107BQ36551637-ED5EFC54-7C5D-4705-AD03-86DA7826DD26Q36568736-38D49906-09D5-4B6A-A74E-A70952F59B75Q36612686-FFCC3D27-49E7-4E58-8162-A9219EBCAEEFQ36734021-2C70C431-4842-4096-BA9D-25894B5D709CQ36745330-87E8EFD5-0B76-417D-824C-BCE1F223E3EF
P2860
Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Intravenous iron optimizes the ...... open-label, randomized trial.
@en
Intravenous iron optimizes the ...... open-label, randomized trial.
@nl
type
label
Intravenous iron optimizes the ...... open-label, randomized trial.
@en
Intravenous iron optimizes the ...... open-label, randomized trial.
@nl
prefLabel
Intravenous iron optimizes the ...... open-label, randomized trial.
@en
Intravenous iron optimizes the ...... open-label, randomized trial.
@nl
P2093
P921
P356
P1476
Intravenous iron optimizes the ...... open-label, randomized trial.
@en
P2093
Alan Ackerman
Harold Ballard
Huzefa Bahrain
J Richard Trout
Jeevindra Rana
Lance Barker
Marilyn McIlwain
Michael Auerbach
Stefan Balan
P304
P356
10.1200/JCO.2004.08.119
P407
P577
2004-04-01T00:00:00Z